Cargando…
Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin
BACKGROUND: Leukocyte- and platelet-rich fibrin (L-PRF) is an autologous matrix scaffold which regulates inflammation by stimulating cytokines and growth factors that are involved in the immune response. L-PRF is suggested as a viable adjunctive method to surgical interventions due to its advantages...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638116/ https://www.ncbi.nlm.nih.gov/pubmed/34852823 http://dx.doi.org/10.1186/s12903-021-01965-7 |
_version_ | 1784608888159469568 |
---|---|
author | Özalp, Öznur Yıldırımyan, Nelli Öztürk, Canan Kocabalkan, Burak Şimşek Kaya, Göksel Sindel, Alper Altay, Mehmet Ali |
author_facet | Özalp, Öznur Yıldırımyan, Nelli Öztürk, Canan Kocabalkan, Burak Şimşek Kaya, Göksel Sindel, Alper Altay, Mehmet Ali |
author_sort | Özalp, Öznur |
collection | PubMed |
description | BACKGROUND: Leukocyte- and platelet-rich fibrin (L-PRF) is an autologous matrix scaffold which regulates inflammation by stimulating cytokines and growth factors that are involved in the immune response. L-PRF is suggested as a viable adjunctive method to surgical interventions due to its advantages on tissue healing. This study aims to retrospectively evaluate the adjunctive role of L-PRF in surgically treated medication-related osteonecrosis of the jaws (MRONJ) patients. METHODS: Between January 2012 and December 2020, patients with AAOMS stage II and III MRONJ lesions, who were treated surgically with adjunctive use of L-PRF in the authors’ institution were enrolled. Surgical interventions consisted of either marginal resection or sequestrectomy with peripheral ostectomy (SPO) or curettage and L-PRF application. Medical records of these patients were retrospectively reviewed and healing was assessed according to certain parameters including mucosal closure and presence of infection, exposed bone, fistula or radiologic markers of disease progression for a minimum of 12 months. RESULTS: Thirteen patients (7 women and 6 men) with an average age of 72.4 years (± 10.61, range 54–84) were included in the study, nine of whom had AAOMS stage III and four stage II MRONJ. Three patients had a marginal resection, nine patients had sequestrectomy with peripheral ostectomy (SPO) and one patient underwent a curettage procedure. All marginal resection and six SPO patients showed complete healing while four patients, who had SPO or curettage experienced incomplete healing. Mean follow up was 20.1 ± 18.29 months. CONCLUSION: The use of L-PRF may be a favorable adjunctive option in the treatment of MRONJ owing to its favorable effects on tissue repair, ease of application, minimally invasive and cost-effective character and autogenous nature. Trial registration Retrospectively registered. |
format | Online Article Text |
id | pubmed-8638116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86381162021-12-02 Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin Özalp, Öznur Yıldırımyan, Nelli Öztürk, Canan Kocabalkan, Burak Şimşek Kaya, Göksel Sindel, Alper Altay, Mehmet Ali BMC Oral Health Research BACKGROUND: Leukocyte- and platelet-rich fibrin (L-PRF) is an autologous matrix scaffold which regulates inflammation by stimulating cytokines and growth factors that are involved in the immune response. L-PRF is suggested as a viable adjunctive method to surgical interventions due to its advantages on tissue healing. This study aims to retrospectively evaluate the adjunctive role of L-PRF in surgically treated medication-related osteonecrosis of the jaws (MRONJ) patients. METHODS: Between January 2012 and December 2020, patients with AAOMS stage II and III MRONJ lesions, who were treated surgically with adjunctive use of L-PRF in the authors’ institution were enrolled. Surgical interventions consisted of either marginal resection or sequestrectomy with peripheral ostectomy (SPO) or curettage and L-PRF application. Medical records of these patients were retrospectively reviewed and healing was assessed according to certain parameters including mucosal closure and presence of infection, exposed bone, fistula or radiologic markers of disease progression for a minimum of 12 months. RESULTS: Thirteen patients (7 women and 6 men) with an average age of 72.4 years (± 10.61, range 54–84) were included in the study, nine of whom had AAOMS stage III and four stage II MRONJ. Three patients had a marginal resection, nine patients had sequestrectomy with peripheral ostectomy (SPO) and one patient underwent a curettage procedure. All marginal resection and six SPO patients showed complete healing while four patients, who had SPO or curettage experienced incomplete healing. Mean follow up was 20.1 ± 18.29 months. CONCLUSION: The use of L-PRF may be a favorable adjunctive option in the treatment of MRONJ owing to its favorable effects on tissue repair, ease of application, minimally invasive and cost-effective character and autogenous nature. Trial registration Retrospectively registered. BioMed Central 2021-12-01 /pmc/articles/PMC8638116/ /pubmed/34852823 http://dx.doi.org/10.1186/s12903-021-01965-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Özalp, Öznur Yıldırımyan, Nelli Öztürk, Canan Kocabalkan, Burak Şimşek Kaya, Göksel Sindel, Alper Altay, Mehmet Ali Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
title | Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
title_full | Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
title_fullStr | Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
title_full_unstemmed | Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
title_short | Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
title_sort | promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638116/ https://www.ncbi.nlm.nih.gov/pubmed/34852823 http://dx.doi.org/10.1186/s12903-021-01965-7 |
work_keys_str_mv | AT ozalpoznur promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin AT yıldırımyannelli promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin AT ozturkcanan promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin AT kocabalkanburak promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin AT simsekkayagoksel promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin AT sindelalper promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin AT altaymehmetali promisingresultsofsurgicalmanagementofadvancedmedicationrelatedosteonecrosisofthejawsusingadjunctiveleukocyteandplateletrichfibrin |